Quantcast

Latest Olanzapine Stories

2009-07-24 09:07:00

KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its investigational agent SAPHRIS(R) (asenapine) met the primary endpoint over one year of treatment in an extension study in patients with predominant, persistent negative symptoms of schizophrenia. Negative symptoms of schizophrenia include apathy, lack of emotion and poor social functioning, among others. In the study, these symptoms were assessed using the validated...

2009-07-23 07:00:00

WALTHAM, Mass., July 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the patient share of Bristol-Myers Squibb/Otsuka's Abilify has grown in the first three lines of therapy since the 2008 analysis of prescribing trends in newly diagnosed schizophrenia patients. Abilify is second to risperidone (Janssen's Risperdal, generics) in first and second lines of therapy and leads other...

167b538f310d0a90f8e7a8e9b3562fca
2009-07-02 06:25:00

Three interrelated, international studies examining the genetic aspects of schizophrenia and bipolar disorder have found some 30,000 gene variations that may contribute to the mental illnesses.  Researchers say the data paints a far more complex picture of the diseases"”as well as treatment and diagnosis"”than had been previously understood. The three research projects examined DNA samples from a total of 10,000 people with schizophrenia and another 20,000 without.  The...

2009-06-10 17:30:00

ADELPHI, Md., June 10 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted that Zyprexa(R) (olanzapine), an atypical antipsychotic, is effective and acceptably safe for the acute treatment of schizophrenia or manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old. The panel supported the FDA and Lilly's position that if Zyprexa is approved for the two indications, prescribers...

d4e2a612837dd6de7ccdeebd181ed5981
2009-06-05 14:48:00

The US Food and Drug Administration announced on Friday that it is investigating the approval of three popular antipsychotic drugs for children. The three drugs, currently marketed for adult use by AstraZeneca, Pfizer and Eli Lilly and Co, appear to be beneficial in children and adolescents, but FDA regulators said they must determine if the drugs pose a greater risk to younger patients. An agency panel is set to meet next week in order to weigh the risks of the psychiatric drugs in children...

2009-05-18 12:30:00

Three-year data show olanzapine LAI safety findings consistent with oral olanzapine except for injection-related events INDIANAPOLIS, May 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company presented today data on the short- and long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of adults with schizophrenia or schizoaffective disorder. Olanzapine LAI is an investigational formulation that combines the atypical antipsychotic Zyprexa(R) (olanzapine) with...

2009-03-29 12:00:00

SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today inconclusive Phase II clinical trial results from Study HBBI investigating LY2140023 monohydrate, also known as mGlu2/3, for the treatment of patients suffering from acute schizophrenia. In Study HBBI, neither LY2140023 monohydrate, nor the comparator molecule olanzapine, known to be more effective than placebo, separated from placebo. In this particular study, Lilly observed a...

2009-03-27 20:56:07

U.S. doctors have tested a treatment for weight gain caused by some anti-psychotic medications. The randomized, double-blind, placebo-controlled trial, published in Biological Psychiatry, evaluated an add-on treatment known as modafinil -- a drug currently used to increase wakefulness in those with sleep disorders. All of the study subjects -- normal volunteers -- received olanzapine -- commonly used to treat psychotic disorders. Half also received modafinil treatment while the other half...

2009-03-26 10:15:15

Antipsychotic drugs, such as olanzapine (Zyprexa), risperidone (Risperdal) and quetiapine (Seroquel), are commonly used to treat psychotic disorders like schizophrenia, but also bipolar disorder and even behavioral problems related to dementia. Unfortunately, the weight gain commonly experienced with antipsychotic treatment is an important side effect for many patients, and causes many patients to discontinue their use leading to even further problems. Biological Psychiatry, in its April 1st...

2009-03-23 06:00:00

New Indication is One of Three FDA Approvals Spanning Lilly Neuroscience Brands INDIANAPOLIS, March 23 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax(R) (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company (NYSE: LLY) announced today. Symbyax is now the first drug approved by the FDA for the acute treatment of treatment-resistant depression (TRD). "Living with major depressive disorder is difficult and...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.